Chuu CP - Search Results

1

Androgen suppresses proliferation of castration-resistant LNCaP 104-R2 prostate cancer cells through androgen receptor, Skp2, and c-Myc.

Chuu CP, Kokontis JM, Hiipakka RA, Fukuchi J, Lin HP, Lin CY, Huo C, Su LC, Liao S. Chuu CP, et al. Cancer Sci. 2011 Nov;102(11):2022-8. doi: 10.1111/j.1349-7006.2011.02043.x. Epub 2011 Aug 18. Cancer Sci. 2011. PMID: 21781227 Free PMC article.

2

Investigation of the underuse of adrenaline (epinephrine) and prognosis among patients with anaphylaxis at emergency department admission.

Lin YY, Chang HA, Kao YH, Chuu CP, Chiang WF, Chang YC, Li YK, Chu CM, Chan JS, Hsiao PJ. Lin YY, et al. Among authors: chuu cp. Front Med (Lausanne). 2023 Jul 7;10:1163817. doi: 10.3389/fmed.2023.1163817. eCollection 2023. Front Med (Lausanne). 2023. PMID: 37484849 Free PMC article.

3

Antiproliferative effect of liver X receptor agonists on LNCaP human prostate cancer cells.

Fukuchi J, Kokontis JM, Hiipakka RA, Chuu CP, Liao S. Fukuchi J, et al. Among authors: chuu cp. Cancer Res. 2004 Nov 1;64(21):7686-9. doi: 10.1158/0008-5472.CAN-04-2332. Cancer Res. 2004. PMID: 15520170

4

Androgen causes growth suppression and reversion of androgen-independent prostate cancer xenografts to an androgen-stimulated phenotype in athymic mice.

Chuu CP, Hiipakka RA, Fukuchi J, Kokontis JM, Liao S. Chuu CP, et al. Cancer Res. 2005 Mar 15;65(6):2082-4. doi: 10.1158/0008-5472.CAN-04-3992. Cancer Res. 2005. PMID: 15781616

5

Role of androgen receptor in the progression of human prostate tumor cells to androgen independence and insensitivity.

Kokontis JM, Hsu S, Chuu CP, Dang M, Fukuchi J, Hiipakka RA, Liao S. Kokontis JM, et al. Among authors: chuu cp. Prostate. 2005 Dec 1;65(4):287-98. doi: 10.1002/pros.20285. Prostate. 2005. PMID: 16015608

6

Inhibition of tumor growth and progression of LNCaP prostate cancer cells in athymic mice by androgen and liver X receptor agonist.

Chuu CP, Hiipakka RA, Kokontis JM, Fukuchi J, Chen RY, Liao S. Chuu CP, et al. Cancer Res. 2006 Jul 1;66(13):6482-6. doi: 10.1158/0008-5472.CAN-06-0632. Cancer Res. 2006. PMID: 16818617

7

Modulation of liver X receptor signaling as novel therapy for prostate cancer.

Chuu CP, Kokontis JM, Hiipakka RA, Liao S. Chuu CP, et al. J Biomed Sci. 2007 Sep;14(5):543-53. doi: 10.1007/s11373-007-9160-8. Epub 2007 Mar 20. J Biomed Sci. 2007. PMID: 17372849 Review.

8

The liver X receptor agonist T0901317 acts as androgen receptor antagonist in human prostate cancer cells.

Chuu CP, Chen RY, Hiipakka RA, Kokontis JM, Warner KV, Xiang J, Liao S. Chuu CP, et al. Biochem Biophys Res Commun. 2007 Jun 1;357(2):341-6. doi: 10.1016/j.bbrc.2007.03.116. Epub 2007 Mar 28. Biochem Biophys Res Commun. 2007. PMID: 17416342 Free PMC article.

9

Suppression of androgen receptor signaling and prostate specific antigen expression by (-)-epigallocatechin-3-gallate in different progression stages of LNCaP prostate cancer cells.

Chuu CP, Chen RY, Kokontis JM, Hiipakka RA, Liao S. Chuu CP, et al. Cancer Lett. 2009 Mar 8;275(1):86-92. doi: 10.1016/j.canlet.2008.10.001. Epub 2008 Nov 1. Cancer Lett. 2009. PMID: 18977589 Free PMC article.

10

Antiproliferative effect of LXR agonists T0901317 and 22(R)-hydroxycholesterol on multiple human cancer cell lines.

Chuu CP, Lin HP. Chuu CP, et al. Anticancer Res. 2010 Sep;30(9):3643-8. Anticancer Res. 2010. PMID: 20944148

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

117 results

Search Page

Filters